These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 19020220)

  • 21. Incidence of Nephrogenic Systemic Fibrosis Using Gadobenate Dimeglumine in 1423 Patients With Renal Insufficiency Compared With Gadodiamide.
    Bruce R; Wentland AL; Haemel AK; Garrett RW; Sadowski DR; Djamali A; Sadowski EA
    Invest Radiol; 2016 Nov; 51(11):701-705. PubMed ID: 26885631
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Preoperative MRI of potential living-donor-related liver transplantation using a single dose of gadobenate dimeglumine.
    Lim JS; Kim MJ; Kim JH; Kim SI; Choi JS; Park MS; Oh YT; Yoo HS; Lee JT; Kim KW
    AJR Am J Roentgenol; 2005 Aug; 185(2):424-31. PubMed ID: 16037515
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Assessment of utilization and pharmacovigilance based on spontaneous adverse event reporting of gadopentetate dimeglumine as a magnetic resonance contrast agent after 45 million administrations and 15 years of clinical use.
    Knopp MV; Balzer T; Esser M; Kashanian FK; Paul P; Niendorf HP
    Invest Radiol; 2006 Jun; 41(6):491-9. PubMed ID: 16763467
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Enhancement of liver parenchyma after injection of hepatocyte-specific MRI contrast media: a comparison of gadoxetic acid and gadobenate dimeglumine.
    Filippone A; Blakeborough A; Breuer J; Grazioli L; Gschwend S; Hammerstingl R; Heinz-Peer G; Kittner T; Laghi A; Leen E; Lencioni R; Lucidarme O; Remplik P; Robinson PJ; Ruehm SG; Schaefer F; Stoupis C; Tombach B; Valette PJ; Zech CJ; Huppertz A
    J Magn Reson Imaging; 2010 Feb; 31(2):356-64. PubMed ID: 20099349
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Low dose gadobenate dimeglumine for imaging of chronic myocardial infarction in comparison with standard dose gadopentetate dimeglumine.
    Bauner KU; Reiser MF; Huber AM
    Invest Radiol; 2009 Feb; 44(2):95-104. PubMed ID: 19077911
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Quarter-dose (0.025 mmol/kg) gadobenate dimeglumine for abdominal MRI in patients at risk for nephrogenic systemic fibrosis: preliminary observations.
    de Campos RO; Heredia V; Ramalho M; De Toni MS; Lugo-Somolinos A; Fuller ER; Semelka RC
    AJR Am J Roentgenol; 2011 Mar; 196(3):545-52. PubMed ID: 21343495
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intra-individual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine for contrast-enhanced magnetic resonance angiography of the supraaortic vessels at 3 Tesla.
    Bueltmann E; Erb G; Kirchin MA; Klose U; Naegele T
    Invest Radiol; 2008 Oct; 43(10):695-702. PubMed ID: 18791411
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A case of gadobenate dimeglumine-induced anaphylactic shock: a case report.
    Huang J; Liu Z; Jiang C; Xu L; Zheng W
    Ann Palliat Med; 2021 Jun; 10(6):7126-7131. PubMed ID: 34154335
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hepatocellular carcinoma in liver transplantation candidates: detection with gadobenate dimeglumine-enhanced MRI.
    Choi SH; Lee JM; Yu NC; Suh KS; Jang JJ; Kim SH; Choi BI
    AJR Am J Roentgenol; 2008 Aug; 191(2):529-36. PubMed ID: 18647927
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Diagnostic performance of gadobenate dimeglumine enhanced MR angiography of the iliofemoral and calf arteries: a large-scale multicenter trial.
    Thurnher S; Miller S; Schneider G; Ballarati C; Bongartz G; Herborn CU; Schoenberg S; Cova MA; Morana G; Niazi K; Iezzi R; Taupitz M; Bluemke DA; Kreitner KF; Kirchin MA; Pirovano G
    AJR Am J Roentgenol; 2007 Nov; 189(5):1223-37. PubMed ID: 17954665
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gadobenate dimeglumine (Gd-DTPA) vs gadopentetate dimeglumine (Gd-BOPTA) for contrast-enhanced magnetic resonance angiography (MRA): improvement in intravascular signal intensity and contrast to noise ratio.
    Pediconi F; Fraioli F; Catalano C; Napoli A; Danti M; Francone M; Venditti F; Nardis P; Passariello R
    Radiol Med; 2003; 106(1-2):87-93. PubMed ID: 12951555
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Assessment of adverse reaction rates during gadoteridol-enhanced MR imaging in 28,078 patients.
    Morgan DE; Spann JS; Lockhart ME; Winningham B; Bolus DN
    Radiology; 2011 Apr; 259(1):109-16. PubMed ID: 21248237
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Small bowel angioedema due to intravenous administration of gadobenate dimeglumine.
    Maarek R; Sellier N; Seror O; Sutter O
    Diagn Interv Imaging; 2019; 100(7-8):459-460. PubMed ID: 30935862
    [No Abstract]   [Full Text] [Related]  

  • 34. Contrast-enhanced MR angiography of the run-off vasculature: intraindividual comparison of gadobenate dimeglumine with gadopentetate dimeglumine.
    Knopp MV; Giesel FL; von Tengg-Kobligk H; Radeleff J; Requardt M; Kirchin MA; Hentrich HR
    J Magn Reson Imaging; 2003 Jun; 17(6):694-702. PubMed ID: 12766899
    [TBL] [Abstract][Full Text] [Related]  

  • 35. MR enterography under the age of 10 years: a single institutional experience.
    Mollard BJ; Smith EA; Lai ME; Phan T; Christensen RE; Dillman JR
    Pediatr Radiol; 2016 Jan; 46(1):43-9. PubMed ID: 26224108
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Visualization of the biliary tract using gadobenate dimeglumine: preliminary findings.
    Ergen FB; Akata D; Sarikaya B; Kerimoglu U; Hayran M; Akhan O; Hussain HK
    J Comput Assist Tomogr; 2008; 32(1):54-60. PubMed ID: 18303288
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Investigation of the longitudinal relaxation rate of blood after gadobenate dimeglumine administration: sequence optimization, dynamic acquisition, and clinical impact for contrast-enhanced MR angiography of the carotid arteries.
    Neira C; Anzidei M; Napoli A; Kirchin MA; Cavallo Marincola B; Zaccagna F; Catalano C; Passariello R; Tedoldi F
    Invest Radiol; 2011 Dec; 46(12):774-82. PubMed ID: 21730871
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The value of gadobenate dimeglumine-enhanced hepatobiliary-phase MR imaging for the differentiation of scirrhous hepatocellular carcinoma and cholangiocarcinoma with or without hepatocellular carcinoma.
    Jeon TY; Kim SH; Lee WJ; Lim HK
    Abdom Imaging; 2010 Jun; 35(3):337-45. PubMed ID: 19350315
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Breakthrough Reactions to Gadobenate Dimeglumine.
    Bhatti ZS; Mervak BM; Dillman JR; Davenport MS
    Invest Radiol; 2018 Sep; 53(9):551-554. PubMed ID: 29470193
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Retrospective assessment of prevalence of nephrogenic systemic fibrosis (NSF) after implementation of a new guideline for the use of gadobenate dimeglumine as a sole contrast agent for magnetic resonance examination in renally impaired patients.
    Abujudeh HH; Rolls H; Kaewlai R; Agarwal S; Gebreananya ZA; Saini S; Schaefer PW; Kay J
    J Magn Reson Imaging; 2009 Dec; 30(6):1335-40. PubMed ID: 19937927
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.